On February 2, 2023 Ashvattha Therapeutics ("Ashvattha"), a clinical-stage company leveraging its nanomedicine technology, hydroxyl dendrimers (HDs), to develop a new class of precision medicines, reported that the Company will provide a corporate overview at two upcoming investor conferences (Press release, Ashvattha Therapeutics, FEB 2, 2023, View Source [SID1234626758]). The corporate overview will highlight the company’s innovative approach to precision nanomedicine through its proprietary hydroxyl dendrimer therapies.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Details for the presentations are as follows:

2023 BIO CEO & Investor Conference
Date: Monday, February 6, 2023
Time: 2:15 PM ET
Location: Palace Room, Marriott Marquis, New York, and virtual
Biocom California’s 13th Annual Global Life Science Partnering & Investor Conference
Date: Wednesday, March 1, 2023
Time: 4:09 PM PT
Location: Charles Fries Room, The Lodge at Torrey Pines, La Jolla, California
Jeffrey Cleland, Ph.D., Chairman, Chief Executive Officer, and President of Ashvattha will be available for one-on-one meetings onsite with registered attendees.

On February 2, 2023 Anaveon, a clinical stage, immuno-oncology company, reported the first patient has been dosed in the OMNIA-1 study – a Phase I/II study assessing the efficacy and safety of ANV419 for the treatment of advanced melanoma. ANV419 is a powerful, IL-2Rbeta selective IL-2 agonist, which has been specifically designed to enable the delivery of high dose IL-2 (Press release, Anaveon, FEB 2, 2023, View Source [SID1234626757]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"In the first-in-human study, the data demonstrate the ability of ANV419 to be delivered at high molar equivalents of IL-2 in a tolerable and convenient way, with preferential stimulation and expansion of NK and CD8+ T cells," said Eduard Gasal, MD, Chief Medical Officer at Anaveon. "We are excited to continue the development of our next-generation IL-2 in patients with advanced melanoma."

In the past decade, there has been steady progress in the development of targeted therapy and immunotherapy for metastatic cutaneous melanoma with a substantial increase in the 5‑year overall survival (OS) rates from less than 10% to up to 50%. Despite substantial progress, 30% to 70% of patients do not respond to initial anti-programmed death 1/ligand 1 (PD-1/L1) therapy, and approximately 25% eventually progress. Thus, the overall outlook for patients with metastatic cutaneous melanoma remains challenging and the development of new effective and tolerable therapy is needed1.

About the OMNIA-1 study
This global, open label, randomized, parallel arm, Phase I/II study (ANV419-101) will enrol up to 130 patients with advanced cutaneous melanoma. The study consists of a monotherapy dose expansion part, followed by a combination part of ANV419 with anti-PD1 or anti-CTLA-4 in patients who have progressed on or following standard of care immunotherapy2.

Anaveon expects to report initial safety and efficacy data of the OMNIA-1 study by early 2024.

Anaveon is conducting several Phase I/II trials in parallel in solid tumors and hematological malignancies. In addition, Anaveon continues its work in developing follow-on compounds to expand on the success of ANV419 by delivering the IL-2 agonist to tumor fighting cells and expand into less immunogenic tumors. The Company is building on its cytokine engineering expertise with preclinical-stage programs harnessing the power of cytokines for therapeutic purposes.

On February 2, 2023 Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a leader in the field of cellular metabolism pioneering therapies for rare diseases, reported the company will host a conference call and live webcast on Thursday, February 23, 2023, at 8:00 a.m. ET to report its fourth quarter and year end 2022 financial results and other business highlights (Press release, Agios Pharmaceuticals, FEB 2, 2023, https://investor.agios.com/news-releases/news-release-details/agios-webcast-conference-call-fourth-quarter-and-year-end-2022 [SID1234626756]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live webcast can be accessed under "Events & Presentations" in the Investors section of the company’s website at www.agios.com. The webcast will be archived and made available for replay on the company’s website beginning approximately two hours after the event.

On February 2, 2023 CTI BioPharma Corp. (Nasdaq: CTIC) reported that senior leadership will participate in a Fireside Chat at the following investor conferences in February 2023 (Press release, CTI BioPharma, FEB 2, 2023, View Source [SID1234626737]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Guggenheim Partners 5th Annual Oncology Conference
Wednesday, February 8, 2023
10:45 a.m. ET
New York, NY

SVB Securities Global Biopharma Conference
Wednesday, February 15, 2023
3:40 p.m. ET
Virtual

The presentations will be webcast live and available for replay from the Investors section of CTI BioPharma’s website at www.ctibiopharma.com.

On February 2, 2023 POINT Biopharma Global Inc. (NASDAQ: PNT) (the "Company" or "POINT"), a company accelerating the discovery, development, and global access to life-changing radiopharmaceuticals, reported management will participate in the following upcoming investor conferences (Press release, Point Biopharma, FEB 2, 2023, View Source [SID1234626736]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Guggenheim 5th Annual Oncology Conference

Format: Fireside Chat and 1×1 Meetings

Location: New York, NY

Date: Wednesday, February 8, 2023

Time: 2:10 pm ET

‍
SVB Securities Global Biopharma Conference

Format: Fireside Chat and 1×1 Meetings

Location: Virtual

Date: Thursday, February 16, 2023

Time: 11:20 am ET

‍
Cowen 43rd Annual Health Care Conference

Format: GI/GU Oncology Panel Discussion and 1×1 Meetings

Location: Boston, MA

Date: Tuesday, March 7, 2023

Time: 12:50pm ET

‍
Oppenheimer 33rd Annual Healthcare Investor Conference

Format: Fireside Chat and 1×1 Meetings

Location: Virtual

Date: Monday, March 13, 2023

Time: 8:40am ET

‍
2023 Bloom Burton & Co. Healthcare Investor Conference

Format: Presentation and 1×1 Meetings

Location: Toronto, ON

Dates: Tuesday, April 25 and Wednesday, April 26, 2023

‍